TYF-IL-2Rg gene-modified autologous stem cells(Shenzhen Geno-Immune Medical Institute)(TYF-IL-2Rg gene-modified autologous stem cells(Shenzhen Geno-Immune Medical Institute))

概要

基本信息

药物类型

基因疗法、造血干细胞疗法

别名-

靶点

IL-2Rγ

作用机制

IL-2Rγ刺激剂(白介素-2受体γ亚基刺激剂)

治疗领域

免疫系统疾病遗传病与畸形内分泌与代谢疾病+ [1]

在研适应症

X连锁联合免疫缺陷疾病

非在研适应症-

原研机构

Shenzhen Geno-Immune Medical Institute

在研机构

Shenzhen Geno-Immune Medical Institute

非在研机构-

最高研发阶段临床1/2期

首次获批日期-

最高研发阶段(中国)临床1/2期

特殊审评-

登录后查看时间轴

关联

2

项与 TYF-IL-2Rg gene-modified autologous stem cells(Shenzhen Geno-Immune Medical Institute) 相关的临床试验

NCT03217617 / Recruiting临床1/2期IIT

Gene Therapy for X-linked Severe Combined Immunodeficiency (SCID-X1) Via Direct Intravenous Injection of Lentiviral Vector (Ivlv-X1)

This is a Phase I/II gene therapy trial treating X-linked severe combined immunodeficiency (SCID-X1) using a self-inactivating lentiviral vector (ivlv-X1) to functionally correct the genetic defect. The primary objectives are to evaluate the safety and efficacy of the direct intravenous lentiviral gene transfer protocol.

开始日期2024-06-30

申办/合作机构

Shenzhen Geno-Immune Medical Institute

NCT03645486 / Unknown statusN/AIIT

Lentiviral Gene Therapy for Chronic Granulomatous Disease (CGD)

This is a Phase I/II clinical trial of gene therapy for treating Chronic Granulomatous Disease using a high-safety, high-efficiency, self-inactivating lentiviral vector TYF to functionally correct the defective gene. The objectives are to evaluate the safety and efficacy of the TYF-CGD gene transfer clinical protocol.

开始日期2018-07-01

申办/合作机构

Shenzhen Geno-Immune Medical Institute

100 项与 TYF-IL-2Rg gene-modified autologous stem cells(Shenzhen Geno-Immune Medical Institute) 相关的临床结果

登录后查看更多信息

100 项与 TYF-IL-2Rg gene-modified autologous stem cells(Shenzhen Geno-Immune Medical Institute) 相关的转化医学

登录后查看更多信息

100 项与 TYF-IL-2Rg gene-modified autologous stem cells(Shenzhen Geno-Immune Medical Institute) 相关的专利（医药）

登录后查看更多信息

100 项与 TYF-IL-2Rg gene-modified autologous stem cells(Shenzhen Geno-Immune Medical Institute) 相关的药物交易

登录后查看更多信息